ALXO
ALX ONCOLOGY HOLDINGS INC
$1.58
+3.95%
$212.6M
No data for this timeframe.
Vol
Market Cap$212.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders35 funds
Inst. Value$81.0M
Inst. Activity7 buys / 1 sells
Insider Activity1B / 3S
Insider Net $$5.0M
SEC Reports6
Press Releases2
Recent Activity
Jun 12, 2026
SEC
A mixed institutional cluster in ALXO for Q3 2024 shows 6 buyers (net +$124K) and 4 sellers (net -$3.74M), dominated by
INST-CLUSTER — Impact 5/10
May 8, 2026
SEC
ALX Oncology reported Q1 2026 GAAP net loss of ($17.9) million, or ($0.17) per share, narrowing from ($0.58) per share i
8-K — Impact 5/10
May 8, 2026
SEC
ALX Oncology reported Q1 2026 GAAP EPS of -$0.17, significantly missing the consensus estimate of -$0.16 (a -6.25% miss)
PRESS-RELEASE — Impact 6/10
May 8, 2026
earnings
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><strong><em>- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at
Apr 16, 2026
Insider
Knight Jeff E. was granted 800,000 shares
Chief Dev & Operating Officer
Apr 16, 2026
Insider
Klencke Barbara was granted 100,000 shares
Chief Medical Officer
Mar 19, 2026
Insider
Lettmann Jason sold 12,311 shares
CHIEF EXECUTIVE OFFICER @ $2.17 ($26.7K)
Inst.
RA CAPITAL MANAGEMENT, L.P. — NEW
13,011,849 shares ($26.1M)
Price Targets
$4.60
+191.1% upside
Strong Buy
Current $1.58
Low $4.00
Median $4.00
High $6.00
5 analysts
$4.00
$6.00
Analyst Ratings
3Strong Buy
8Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 19, 2026 | Wells Fargo | INITIATE | Overweight |
| Mar 10, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 5, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.16 | $-0.16 — $-0.16 | 65% YoY | 1 |
| Next Q | $-0.16 | $-0.16 — $-0.16 | 1 | |
| Current FY | $-0.65 | $-0.65 — $-0.65 | 61% YoY | 1 |
| Next FY | $-0.54 ▲ +12.4% | $-0.54 — $-0.54 | 17% YoY | 1 |
Latest Reports
BEARISH
INST-CLUSTER
5/10
A mixed institutional cluster in ALXO for Q3 2024 shows 6 buyers (net +$124K) and 4 sellers (net -$3.74M), dominated by
Jun 12, 2026
NEUTRAL
8-K
5/10
ALX Oncology reported Q1 2026 GAAP net loss of ($17.9) million, or ($0.17) per share, narrowing from ($0.58) per share i
May 8, 2026
NEUTRAL
Press
4/10
ALX Oncology presented exploratory Phase 1b/2 data at ESMO Breast Cancer 2026 showing that evorpacept plus zanidatamab a
May 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $26.1M | NEW |
| Blackstone Inc. | $11.7M | NEW |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $11.5M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.4M | — |
| MARSHALL WACE, LLP | $7.5M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 16, 2026 | Knight Jeff | A | $0.00 |
| Apr 16, 2026 | Klencke Barbara | A | $0.00 |
| Mar 19, 2026 | Lettmann Jason | SELL | $26.7K |
| Mar 19, 2026 | Pinto Shelly | SELL | $2.0K |
| Mar 3, 2026 | Klencke Barbara | A | $0.00 |
35 institutional holders with $81.0M total value (40,378,223 shares) as of 2026-Q1. Top holders: RA, Blackstone, DRIEHAUS. Net buying activity: 7 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 13,011,849 | $26.1M | 32.2% | NEW |
| 2 | Blackstone Inc. | 5,826,544 | $11.7M | 14.5% | NEW |
| 3 | DRIEHAUS CAPITAL MANAGEMENT LLC | 5,734,620 | $11.5M | 14.2% | DOUBLED +303.0% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4,179,736 | $8.4M | 10.4% | — |
| 5 | MARSHALL WACE, LLP | 3,757,216 | $7.5M | 9.3% | DOUBLED +14144.8% |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,000,000 | $4.0M | 5.0% | — |
| 7 | TWO SIGMA INVESTMENTS, LP | 1,587,833 | $3.2M | 3.9% | ADD +26.9% |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,328,907 | $2.7M | 3.3% | — |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 732,599 | $1.5M | 1.8% | ADD +73.2% |
| 10 | BANK OF AMERICA CORP /DE/ | 577,783 | $1.2M | 1.4% | TRIM -48.7% |
| 11 | BlackRock, Inc. | 447,799 | $897.8K | 1.1% | TRIM -37.5% |
| 12 | VANGUARD FIDUCIARY TRUST CO | 294,478 | $590.4K | 0.7% | — |
| 13 | STATE STREET CORP | 175,828 | $352.5K | 0.4% | ADD +41.5% |
| 14 | GOLDMAN SACHS GROUP INC | 138,593 | $277.9K | 0.3% | — |
| 15 | MORGAN STANLEY | 98,835 | $198.2K | 0.2% | TRIM -27.4% |
| 16 | VANGUARD PORTFOLIO MANAGEMENT LLC | 97,881 | $196.3K | 0.2% | — |
| 17 | Brevan Howard Capital Management LP | 79,389 | $159.2K | 0.2% | — |
| 18 | OMERS ADMINISTRATION Corp | 75,000 | $150.4K | 0.2% | — |
| 19 | Point72 Asset Management, L.P. | 41,095 | $82.4K | 0.1% | DOUBLED +103.3% |
| 20 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 37,997 | $74.9K | 0.1% | ADD +27.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 13,011,849 | — | $26.1M | 2026-Q1 |
| Blackstone Inc. | NEW | — | 5,826,544 | — | $11.7M | 2026-Q1 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | DOUBLED | 1,422,882 | 5,734,620 | +303.0% | $11.5M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 26,376 | 3,757,216 | +14144.8% | $7.5M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 423,099 | 732,599 | +73.2% | $1.5M | 2026-Q1 |
| STATE STREET CORP | ADD | 124,228 | 175,828 | +41.5% | $352.5K | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 20,217 | 41,095 | +103.3% | $82.4K | 2026-Q1 |
| CWM, LLC | TRIM | 96 | 65 | -32.3% | $130.00 | 2026-Q1 |
| CWM, LLC | TRIM | 144 | 96 | -33.3% | — | 2025-Q4 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | ADD | 795,777 | 1,422,882 | +78.8% | $1.6M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 164,499 | 423,099 | +157.2% | $478.1K | 2025-Q4 |
| MARSHALL WACE, LLP | TRIM | 39,583 | 26,376 | -33.4% | $29.8K | 2025-Q4 |
| COMMONWEALTH EQUITY SERVICES, LLC | TRIM | 20,572 | 15,102 | -26.6% | $17.1K | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 1,304 | 144 | -89.0% | — | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 477,934 | 606,671 | +26.9% | $1.1M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,035,127 | 530,828 | -48.7% | $971.4K | 2025-Q3 |
| BANK OF MONTREAL /CAN/ | TRIM | 668,747 | 474,781 | -29.0% | $868.8K | 2025-Q3 |
| BlackRock, Inc. | TRIM | 716,297 | 447,692 | -37.5% | $819.3K | 2025-Q3 |
| UBS Group AG | TRIM | 288,685 | 172,570 | -40.2% | $315.8K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 85,399 | 164,499 | +92.6% | $301.0K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 117,465 | 85,290 | -27.4% | $156.1K | 2025-Q3 |
| MARSHALL WACE, LLP | TRIM | 106,280 | 39,583 | -62.8% | $72.4K | 2025-Q3 |
| FMR LLC | TRIM | 18,033 | 12,986 | -28.0% | $23.8K | 2025-Q3 |
| FEDERATED HERMES, INC. | TRIM | 6,541 | 2,374 | -63.7% | $4.3K | 2025-Q3 |
| PNC FINANCIAL SERVICES GROUP, INC. | TRIM | 397 | 100 | -74.8% | $183.00 | 2025-Q3 |
5 unique insiders with 7 transactions. Net insider value: $5.0M ($5.0M bought, $30.0K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 16, 2026 | Knight Jeff E. | Chief Dev & Operating Officer | AWARD | 800,000 | — | — |
| Apr 16, 2026 | Klencke Barbara | Chief Medical Officer | AWARD | 100,000 | — | — |
| Mar 19, 2026 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | SELL | 12,311 | $2.17 | $26.7K |
| Mar 19, 2026 | Pinto Shelly | SVP, FINANCE AND CAO | SELL | 903 | $2.17 | $2.0K |
| Mar 3, 2026 | Klencke Barbara | Chief Medical Officer | AWARD | 700,000 | — | — |
| Feb 18, 2026 | Pinto Shelly | SVP, FINANCE AND CAO | SELL | 565 | $2.27 | $1.3K |
| Feb 2, 2026 | GOODMAN COREY S | Director | BUY | 3,184,713 | $1.57 | $5.0M |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 3 neutral. Avg impact: 4.8/10.
BEARISH
INST-CLUSTER
5/10
A mixed institutional cluster in ALXO for Q3 2024 shows 6 buyers (net +$124K) and 4 sellers (net -$3
Jun 12, 2026
NEUTRAL
8-K
5/10
ALX Oncology reported Q1 2026 GAAP net loss of ($17.9) million, or ($0.17) per share, narrowing from
May 8, 2026
BEARISH
PRESS-RELEASE
6/10
ALX Oncology reported Q1 2026 GAAP EPS of -$0.17, significantly missing the consensus estimate of -$
May 8, 2026
NEUTRAL
8-K
3/10
ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer on April 13, 2026, wit
Apr 13, 2026
NEUTRAL
CLUSTER
3/10
Two corporate insiders at ALX Oncology sold shares in a coordinated open-market transaction on March
Mar 23, 2026
BULLISH
INST-CLUSTER
7/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased th
Feb 28, 2026
Current analyst consensus: Strong Buy (85% buy). Based on 13 analysts: 3 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$4.60 mean target
+191.1% upside
Strong Buy (1.43)
$4.00 Low
$6.00 High
| Metric | Value |
|---|---|
| Current Price | $1.58 |
| Target Low | $4.00 |
| Target Mean | $4.60 |
| Target Median | $4.00 |
| Target High | $6.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.43) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.16 | $-0.16 | $-0.16 | 64.8% | +0.0% | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.16 | $-0.16 | $-0.16 | — | +0.0% | — | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.65 | $-0.65 | $-0.65 | 60.8% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-0.54 | $-0.54 | $-0.54 | 17.1% | +12.4% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.156 | |
| 7d ago | $-0.156 | |
| 30d ago | $-0.156 | |
| 60d ago | $-0.156 | |
| 90d ago | $-0.220 | +0.064 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 19, 2026 | Wells Fargo | INITIATE | — | Overweight |
| Mar 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 5, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Jan 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 8, 2026
earnings
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><strong><em>- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with c
May 8, 2026
earnings_calendar
ALXO Q1 2026 Earnings Scheduled — 2026-05-08
May 7, 2026
fda
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
<p align="center"><strong><em>- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a </em></strong><strong><em>biomarker
May 7, 2026
earnings_calendar
ALXO Q1 2026 Earnings Scheduled — 2026-05-07
Apr 17, 2026
other
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
<p>SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biote
Apr 13, 2026
other
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
<p align="center"><strong><em>- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development
Apr 7, 2026
short_volume
Short Volume: ALXO — 59.9% short (0.4M / 0.6M)
Short: 357,452 | Exempt: 5,784 | TRF Vol: 597,233 | Short Ratio: 59.9% | Off-exchange volume (dark pool + OTC)
Mar 25, 2026
short_volume
Short Volume: ALXO — 67.4% short (0.4M / 0.5M)
Short: 357,296 | Exempt: 1,609 | TRF Vol: 529,822 | Short Ratio: 67.4% | Off-exchange volume (dark pool + OTC)
Feb 27, 2026
earnings
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
ALX Oncology Q4 and EOY 2025 earnings press release
Feb 27, 2026
earnings_calendar
ALXO Q4 2025 Earnings After Market Close — 2026-02-27